Estimated 54 million people suffer from obstructive sleep apnea in the U.S. including 30-50% of adults with hypertension, both conditions associated with excess morbidity and mortality – – Obstructive ...

NObesity, a well-known weight loss clinic specializing in state-of-the-art bariatric surgery, has successfully performed a life-changing procedure on 61-year-old Jayeshkumar Jani, marking a ...

Recognizing the rise of conditions like Obstructive Sleep Apnea (OSA), the hospital offers comprehensive sleep studies to diagnose and treat this common ailment effectively. OSA disrupts sleep by ...

Discover the evolving landscape of wellness in India, from traditional practices to specialized programs addressing modern ...

Do you experience an inclination for snoring, daytime sleepiness, obesity, high blood pressure, impaired concentration and ...

The S&P 500 and the Dow fell on Monday in holiday-thinned trading after a stopgap government funding bill averted a U.S.

Eli Lilly (LLY) advanced over +1% in pre-market trading after the FDA approved the company’s weight-loss drug Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity.

The Duct Fans market is poised for an extraordinary ascent in the coming decade. Projections indicate that the market will ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

Tirzepatide is the active ingredient in Zepbound, the FDA approved prescription medicine for Obstructive Sleep Apnea.

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...